» Articles » PMID: 23190892

Familial Melanoma-associated Mutations in P16 Uncouple Its Tumor-suppressor Functions

Overview
Publisher Elsevier
Specialty Dermatology
Date 2012 Nov 30
PMID 23190892
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Familial melanoma is associated with point mutations in the cyclin-dependent kinase (CDK) inhibitor p16(INK4A) (p16). We recently reported that p16 regulates intracellular oxidative stress in a cell cycle-independent manner. Here we constructed 12 different familial melanoma-associated point mutants spanning the p16 coding region and analyzed their capacity to regulate cell cycle phase and suppress reactive oxygen species (ROS). Compared with wild-type p16, which fully restored both functions in p16-deficient fibroblasts, various p16 mutants differed in their capacity to normalize ROS and cell cycle profiles. Although some mutations did not impair either function, others impaired both. Interestingly, several mutations impaired cell cycle (R24Q, R99P, and V126D) or oxidative functions (A36P, A57V, and P114S) selectively, indicating that these two functions of p16 can be uncoupled. Similar activities were confirmed with selected mutants in human melanoma cells. Many mutations impairing both cell cycle and oxidative functions, or only cell cycle function, localize to the third ankyrin repeat of the p16 molecule. Alternatively, most mutations impairing oxidative but not cell cycle function, or those not impairing either function, lie outside this region. These results demonstrate that particular familial melanoma-associated mutations in p16 can selectively compromise these two independent tumor-suppressor functions, which may be mediated by distinct regions of the protein.

Citing Articles

Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.

Zhao Z, Li X, Wang F, Xu Y, Liu S, Han Q Cancer Med. 2023; 12(10):11672-11685.

PMID: 36999792 PMC: 10242355. DOI: 10.1002/cam4.5871.


Focus on the Contribution of Oxidative Stress in Skin Aging.

Papaccio F, D Arino A, Caputo S, Bellei B Antioxidants (Basel). 2022; 11(6).

PMID: 35740018 PMC: 9220264. DOI: 10.3390/antiox11061121.


Evaluation of Bioactive Properties of Lipophilic Fractions of Edible and Non-Edible Parts of (Watercress) in a Model of Human Malignant Melanoma Cells.

Kyriakou S, Tragkola V, Alghol H, Anestopoulos I, Amery T, Stewart K Pharmaceuticals (Basel). 2022; 15(2).

PMID: 35215254 PMC: 8879096. DOI: 10.3390/ph15020141.


TERT Promoter Revertant Mutation Inhibits Melanoma Growth through Intrinsic Apoptosis.

Wang Y, Chen Y, Li C, Xiao Z, Yuan H, Zhang Y Biology (Basel). 2022; 11(1).

PMID: 35053139 PMC: 8773187. DOI: 10.3390/biology11010141.


Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance.

Kimura H, Paranal R, Nanda N, Wood L, Eshleman J, Hruban R Elife. 2022; 11.

PMID: 35001868 PMC: 8824478. DOI: 10.7554/eLife.71137.


References
1.
Serrano M, Hannon G, Beach D . A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993; 366(6456):704-7. DOI: 10.1038/366704a0. View

2.
Macip S, Igarashi M, Berggren P, Yu J, Lee S, Aaronson S . Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol Cell Biol. 2003; 23(23):8576-85. PMC: 262651. DOI: 10.1128/MCB.23.23.8576-8585.2003. View

3.
Serizawa H . Cyclin-dependent kinase inhibitor p16INK4A inhibits phosphorylation of RNA polymerase II by general transcription factor TFIIH. J Biol Chem. 1998; 273(10):5427-30. DOI: 10.1074/jbc.273.10.5427. View

4.
Goldstein A, Chan M, Harland M, Hayward N, Demenais F, Bishop D . Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet. 2006; 44(2):99-106. PMC: 2598064. DOI: 10.1136/jmg.2006.043802. View

5.
Jenkins N, Liu T, Cassidy P, Leachman S, Boucher K, Goodson A . The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene. 2010; 30(3):265-74. PMC: 3003740. DOI: 10.1038/onc.2010.419. View